

CORRECTION

Open Access



Correction: ^{18}F -FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis

Sébastien Heyer¹, Maïa Simon², Matthieu Doyen^{1,3}, Ali Mortada¹, Véronique Roch¹, Elodie Jeanbert², Nathalie Thilly², Catherine Malaplate⁴, Anna Kearney-Schwartz^{5,6}, Thérèse Jonveaux^{6,7}, Aurélie Bannay⁸ and Antoine Verger^{1,3*}

Correction: *Alz Res Therapy* 16, 182 (2024)
<https://doi.org/10.1186/s13195-024-01535-3>

Following publication of the original article [1], corrections were made to the three numbers (1), (2), (3) in Methods section of Abstract that were incorrectly presented as reference citations: (Prince M, Wimo A, Guerchet Maëlénn, Ali G-C, Wu Y-T et al. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. [Research Report] Alzheimer's Disease International. 2015. 2015.); (Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn

B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14(4):535–62.) and (Davis M, O'Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. *CAR.* 2018;15(8):777–88.).

The original article [1] has been updated.

Published online: 13 November 2024

References

1. Heyer S, Simon M, Doyen M, et al. ^{18}F -FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. *Alz Res Therapy.* 2024;16:182. <https://doi.org/10.1186/s13195-024-01535-3>.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1186/s13195-024-01535-3>.

*Correspondence:

Antoine Verger
a.verger@chru-nancy.fr

¹Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, Nancy F-54000, France

²Department of Methodology, Promotion and Investigation, Université de Lorraine, CHRU-Nancy, Nancy F-54000, France

³Université de Lorraine, IADl, INSERM U1254, Nancy F-54000, France

⁴Department of Biochemistry, Université de Lorraine, CHRU-Nancy, Nancy F-54000, France

⁵Department of Geriatrics, Université de Lorraine, CHRU-Nancy, Nancy F-54000, France

⁶CMRR, University Hospital Nancy, Nancy F-54000, France

⁷Department of Neurology, University Hospital Nancy, Nancy F-54000, France

⁸Medical Assessment and Information Department, Université de Lorraine, CHRU-Nancy, Nancy 54000, France



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.